Recent research have centered on the convergence of glucagon-like peptide-1|GIP|GCGR agonist therapies and dopaminergic signaling. While GIP activators are commonly employed for managing type 2 diabetes mellitus, their potential impacts on reinforcement circuits, specifically governed by DA syste